Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Accent Microcell Ltd

Healthcare | Small Cap

Accent Microcell Ltd Health Insights
Health Score : 7.96Health Score : 7.96

Accent Microcell Ltd demonstrates robust financial health, characterized by exceptional growth and outstanding profitability. The company is expanding at a very rapid pace across sales, profits, and its asset base, indicating strong market demand and successful strategic execution. Its profitability is a key strength, with high margins and excellent returns on investment. Furthermore, the company operates with virtually no debt, giving it a superior level of long-term financial stability and very low risk. However, this rapid growth presents challenges in operational efficiency. A notable weakness is the significant amount of time it takes to collect payments from customers, which could strain cash flow. Additionally, the overall effectiveness of using its large capital base to generate sales is low. The company is heavily reinvesting its earnings into expansion, as shown by high capital spending and low dividend payouts. The future outlook is positive, driven by strong growth momentum, but hinges on managing operational efficiencies as it scales.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Accent Microcell Ltd Health Insights
Health Score : 7.96Health Score : 7.96

Accent Microcell Ltd demonstrates robust financial health, characterized by exceptional growth and outstanding profitability. The company is expanding at a very rapid pace across sales, profits, and its asset base, indicating strong market demand and successful strategic execution. Its profitability is a key strength, with high margins and excellent returns on investment. Furthermore, the company operates with virtually no debt, giving it a superior level of long-term financial stability and very low risk. However, this rapid growth presents challenges in operational efficiency. A notable weakness is the significant amount of time it takes to collect payments from customers, which could strain cash flow. Additionally, the overall effectiveness of using its large capital base to generate sales is low. The company is heavily reinvesting its earnings into expansion, as shown by high capital spending and low dividend payouts. The future outlook is positive, driven by strong growth momentum, but hinges on managing operational efficiencies as it scales.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

23.12

Neutral

Industry Median

36.13

Neutral
Neutral

Small Cap Median

35.79

Neutral

P/E RATIO

24.25

P/B RATIO

3.21

Neutral

Industry Median

6.08

Neutral
Overvalued

Small Cap Median

6.08

Overvalued

P/S RATIO

3.03

Neutral

Industry Median

5.75

Neutral
Neutral

Small Cap Median

5.17

Neutral

Others

Highly Undervalued

PEG RATIO

0.47

Highly Undervalued
Overvalued

EV/EBITDA RATIO

16.71

Overvalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹334.1 as on May 29, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 10.00

The company is in a phase of exceptional and widespread growth. It is expanding at an extremely high rate across all major indicators, including revenue, operating profit, and earnings per share. This powerful growth trajectory is supported by a rapid expansion of its asset base, indicating strong market acceptance and successful execution of its expansion strategy. This is a primary strength of the company.

ExcellentRevenue Growth RateExcellent
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
ExcellentAsset Growth RateExcellent
ExcellentNet Income Growth RateExcellent
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate24.8118.6724.877.7231.7
Operating Profit Growth Rate18.1846.15105.267.6935.71
Earnings Per Share (EPS) Growth-59.08105.9952.189.6332.66
Asset Growth Rate17.2816.8484.6811.2241.23
Net Income Growth Rate201001501033.33
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 5.60

The company's financial metrics present a mixed view, resulting in an average score. On the positive side, key per-share value indicators like earnings and book value show healthy growth. However, this is contrasted by low direct returns to shareholders in the form of dividends. The company is also undertaking very high levels of capital expenditure, which signifies a strategy focused on aggressive reinvestment for future growth rather than immediate shareholder payouts.

GoodAdjusted Earnings Per Share (Adjusted EPS)Good
GoodCash Earnings Per Share (Cash EPS)Good
GoodBook Value Per ShareGood
PoorDividend Per Share (DPS)Poor
PoorCapital Expenditures (CapEx)Poor
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)4.629.2314.6815.7118.33
Cash Earnings Per Share (Cash EPS)7.6912.3116.1917.6220.42
Book Value Per Share24.6238.4678.192.86115
Dividend Per Share (DPS)0.720.660.880.830.91
Capital Expenditures (CapEx)44133787
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 10.00

The company's profitability is exceptional across all measures. It is highly effective at turning revenue into profit, as shown by its excellent margins. The returns it generates on the money invested by shareholders (ROE) and on its overall capital base (ROCE) are outstanding. This indicates superior management performance, a strong competitive position in the healthcare services sector, and highly efficient use of its resources to create value.

ExcellentGross Profit MarginExcellent
ExcellentReturn on Capital Employed (ROCE)Excellent
ExcellentReturn on Equity (ROE)Excellent
ExcellentReturn on Assets (ROA)Excellent
ExcellentOperating MarginExcellent
ExcellentNet MarginExcellent
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin5.427.6114.2314.3414.9
Return on Capital Employed (ROCE)1927312425
Return on Equity (ROE)18.752418.2916.9215.94
Return on Assets (ROA)13.6817.1219.0218.4217.7
Operating Margin7.839.6415.8515.8516.33
Net Margin3.616.0912.212.4512.61
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 5.00

The company's operational efficiency is a mixed bag, with an overall average performance. It is good at using its fixed assets to generate sales. However, there are significant weaknesses, particularly the very long time it takes to collect payments from customers, which can tie up cash. Furthermore, the overall efficiency in using its total capital to generate revenue is poor. These inefficiencies are notable areas of concern.

GoodFixed Asset Turnover RatioGood
AverageInventory Turnover RatioAverage
AverageReceivables Turnover RatioAverage
AverageDays Sales in Inventory RatioAverage
PoorReceivable DaysPoor
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio5.536.358.485.526.58
Inventory Turnover Ratio4.364.445.66.789
Receivables Turnover Ratio11.078.385.864.454.47
Days Sales in Inventory Ratio83.7282.2165.1853.8340.56
Receivable Days32.9743.5662.2982.0281.66
Capital Turnover Ratio4.263.551.491.351.26
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 10.00

The company's ability to meet its financial obligations is outstanding. With earnings far exceeding its interest payments, the risk of defaulting on its minimal debt is virtually non-existent. Similarly, profits provide a very large cushion for its dividend payments. This demonstrates superior financial security and a very high quality of earnings, ensuring that its commitments to both creditors and shareholders are extremely safe.

ExcellentInterest Coverage RatioExcellent
ExcellentEquity Dividend Coverage RatioExcellent
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio3.67638N/A59
Equity Dividend Coverage Ratio5.5612.514.2916.6720
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company's long-term financial stability is outstanding and represents a key strength. It operates on a virtually debt-free basis, financing its assets almost entirely through equity. This conservative financial structure means the company has an extremely low risk of financial distress from debt obligations. This position provides maximum long-term security and financial independence, making it highly resilient to economic downturns.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.180.10.0100
Debt to Equity Ratio0.220.110.0100
Equity Ratio0.820.90.9911
Debt To Asset Ratio0.070.050.0100
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 8.38

The company exhibits a very strong capacity to meet its short-term financial obligations. Its holdings of current and quick assets relative to its immediate liabilities are exceptionally high, indicating a substantial financial cushion and minimal short-term risk. This strong position is primarily built on its asset base. A point of relative weakness is that the cash generated directly from its core operations provides less coverage for its current debts, even though the overall liquidity picture remains robust.

ExcellentCurrent RatiosExcellent
ExcellentQuick RatiosExcellent
GoodCash RatiosGood
WeakOperating Cash Flow RatiosWeak
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio1.161.454.435.153.67
Quick Ratio0.440.683.594.12.97
Cash Ratio0.050.041.831.560.44
Operating Cash Flow Ratio0.270.150.280.770.42
01.

Current Ratios

02.

Quick Ratios

03.

Cash Ratios

04.

Operating Cash Flow Ratios

Peer Comparison With 18 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Accent Microcell Ltd7.9624.25Neutral57.0018.2844.00
2Lincoln Pharmaceuticals Ltd7.3114.01Neutral98.0043.8888.00
3NGL Fine Chem Ltd6.9839.22Overvalued73.0067.3948.00
4Medico Remedies Ltd6.6137.70Overvalued17.001.5813.00
5Kilitch Drugs (India) Ltd6.6121.54Neutral37.009.2730.00
6Kopran Ltd6.6025.82Neutral62.006.3026.00
7SMS Lifesciences India Ltd6.5921.20Undervalued45.0070.6819.00
8Infinium Pharmachem Ltd6.4226.90Neutral22.006.4314.00
9Sakar Healthcare Ltd5.8158.66Highly Overvalued69.0013.7030.00
10Medicamen Biotech Ltd5.7332.19Neutral20.006.9410.00
11Albert David Ltd5.63-272.47Neutral5.00-2.62-1.00
12BPL Ltd5.46-31.11Neutral-4.82-3.00-8.55
13Zim Laboratories Ltd5.4141.96Neutral30.001.116.00
14Remus Pharmaceuticals Ltd5.3125.48Neutral57.0020.9746.00
15Ind-Swift Laboratories Ltd4.9539.28Neutral45.004.8941.00
16Venus Remedies Ltd4.8323.37Neutral147.0074.30103.00
17Wanbury Ltd4.6528.62Neutral88.0018.9343.00
18Nectar Lifescience Ltd3.83-2.67Neutral-59.00-2.95-293.00
Management Assessment Summary
OrangeBalanced Management

Management effectiveness is mixed. The company demonstrates outstanding financial performance with exceptional growth in sales and profits, coupled with significantly improving profitability margins. Financial prudence is a major strength, evidenced by a drastic reduction in debt and a very strong interest coverage ratio. However, these strengths are offset by considerable weaknesses in operational efficiency. A sharp increase in the cash conversion cycle and a significant divergence between net profit and cash from operations indicate poor working capital management and low-quality earnings. While growth and profitability are strong, the inability to convert these profits into cash is a significant concern.

ExcellentFinancial Performance & GrowthExcellent
GoodCapital Efficiency & ReturnsGood
ExcellentFinancial Health & PrudenceExcellent
GoodShareholding & Ownership StructureGood
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

The overall risk profile is moderate. The primary risk stems from poor accounting quality, highlighted by a severe disconnect between reported profits and actual cash generation. In FY24, the company generated only ₹11 Cr in cash from operations against a net profit of ₹30 Cr. This discrepancy, driven by a deteriorating working capital cycle and a sharp increase in receivables, raises significant questions about the quality and sustainability of earnings. While the company has very low financial risk due to minimal debt and strong coverage ratios, the operational risk related to cash flow conversion is high. The compelling growth story is clouded by the fundamental risk of non-cash-backed profits.

WeakAccounting QualityWeak
01.

Accounting Quality

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe